CD274 and neoplasm: The aim was to improve the efficacy of ICIs, in particular anti-programmed death receptor-1 (anti-PD-1)/ PD-L1 mAbs, in combination with β-glucans, by inducing PD-L1 tissutal expression and by enhancing a potent and coordinated immune response against tumor cells.